The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients.

D. S. Alberts, H. S. Chen, S. Y. Chang, Y. M. Peng

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

We have studied the disposition of bleomycin, melphalan, or vinblastine after intraperitoneal (IP) instillation in 14 cancer patients. Although IP bleomycin had a somewhat longer terminal-phase plasma half-life than after intravenous (IV) administration (5.5 vs 4.0 h, respectively), its systemic absorption averaged only 44%-52% of the administered dose. IP melphalan's mean terminal-phase half-life of 1.3 h was similar to that seen after IV drug administration. Melphalan's systemic absorption form the IP space averaged only 39% of the administered dose. In contrast, vinblastine plasma levels remained elevated for longer than 24 h after IP instillation. Its use was associated with life-threatening adynamic ileus in two patients. Bleomycin's and melphalan's reduced systemic availability after IP dosing suggests that their dose could be increased safely by a factor of two over their standard IV doses.

Original languageEnglish (US)
Pages (from-to)293-299
Number of pages7
JournalRecent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
Volume74
DOIs
StatePublished - 1980
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients.'. Together they form a unique fingerprint.

  • Cite this